A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer
Evaluate the safety and efficacy of mesothelin-targeting UCAR-T cells in the treatment of mesothelin-positive advanced pancreatic cancer
Advanced Pancreatic Cancers
DRUG: CHT102
Safety and Tolerability, Treatment-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0), 2 years
Objective response rate (ORR), The total response rate after 90 days of treatment with study drug., At 4 weeks, and overall|Disease control rate (DCR), The disease control rate after 90 days of treatment with study drug., At 4 weeks, and overall|Progress-free survival(PFS), PFS will be assessed from the first CHT102 infusion to death from any cause or the first assessment of progression (Assessed based on RECIST criteria), 2 years|Overall survival (OS ), OS will be assessed from the first CHT102 infusion to death from any cause (Assessed based on RECIST criteria), 3 years|pharmacokinetics (PK), Concentration levels of MSLN+ CAR-T cells, 6 months|PD, Concentration levels of MSLN U CAR-T-related serum cytokines, such as IL-2, IL-4, IL-6, IL-10, IFN-γ, TNF-α, etal, 6 months
3 planned dose cohorts will be evaluated during dose escalation phase. The dose expansion will be initiated after SRC (safety review committee) review the avaliable safety, PK and preliminary efficacy data.